The BIRC service of Pixel Wiser mainly focuses on oncology. Sparkle supports a variety of major oncology drug efficacy assessment criteria, such
as RECIST 1.1, Cheson 2007, Lugano 2014, mRECIST, PCWG3, RANO, RANO-BM etc., covering multiple fields such as Solid tumors, Head and Neck
cancer, Respiratory cancer, Gastrointestinal cancer and Gynecologic Cancer. Expertise in over 220 BIRC projects for clinical trials, spanning diverse oncology indications and therapeutic classes, including immunotherapeutic antibodies, targeted small-molecule, Cell & Gene Therapies, and XDC interventions. Focus encompasses patient populations across early-stage tumor, first/second-line systemic therapies, and adjuvant/neoadjuvant treatment paradigms.

Pixel Wiser team also has extensive project experience in the orthopedics field. Sparkle supports clinical trials involving DXA bone density scans (Dual-emission X-ray Absorptiometry), which use low-dose X-rays to measure the penetration (density) of different tissues (bone or soft tissue) based on energy differences. DXA is widely used to determine bone mineral density (BMD)—the gold standard for diagnosing osteoporosis—and predict fracture risk by analyzing BMD changes. This examination typically targets the most common fracture sites, such as the lumbar spine, hip, and wrist.